Ticker >

Zydus Lifesciences share price

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE BSE: 532321 SECTOR: Pharmaceuticals & Drugs  224k   2k   523

900.20
+4.45 (0.50%)
NSE: Today, 10:34 AM

Price Summary

Today's High

₹ 901.6

Today's Low

₹ 891.5

52 Week High

₹ 912.8

52 Week Low

₹ 452.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

91118.62 Cr.

Enterprise Value

95693.02 Cr.

No. of Shares

101.22 Cr.

P/E

36.06

P/B

6.05

Face Value

₹ 1

Div. Yield

0.67 %

Book Value (TTM)

₹  148.71

CASH

248.1 Cr.

DEBT

4822.5 Cr.

Promoter Holding

74.98 %

EPS (TTM)

₹  24.97

Sales Growth

11.42%

ROE

11.38 %

ROCE

13.45%

Profit Growth

78.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Zydus Lifesciences Ltd.

FALCIGO NUCOXIA OCID NUCOXIA MR LINID OXALGIN BURPEX COLIRID PAZUBID OFLIN O NUCOXIA SP TOLFREE IKMAG METSCORE XL OXALGIN MR METSCORE AM ARZEP ZYAQUA LATINA RT BRIOPT MOXTIF ILAZ ZYONATE ZYOPTA MOXTIF K AMNAC ZYVISC CYCLODROP Remdac TwinRab VaxiFlu 4 Aten DERIPHYLLIN DOXOLIN ORNI O NEUROMET DEZOCORT

Index Presence

The company is present in 32 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.42%
3 Year11.22%
5 Year8.49%

Profit Growth

1 Year78.25%
3 Year2.67%
5 Year6.99%

ROE%

1 Year11.38%
3 Year10.09%
5 Year12.32%

ROCE %

1 Year13.45%
3 Year10.85%
5 Year12.37%

Debt/Equity

0.3536

Price to Cash Flow

84.51

Interest Cover Ratio

8.30481667864845

CFO/PAT (5 Yr. Avg.)

0.952258626646837

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 74.98 0
Sep 2023 74.98 0
Jun 2023 74.98 0
Mar 2023 74.98 0
Dec 2022 74.98 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.30481667864845.
  • The Company has been maintaining an effective average operating margins of 25.2778437006827% in the last 5 years.
  • Company’s PEG ratio is 0.448690569779417.
  • The company has an efficient Cash Conversion Cycle of 50.4591225927301 days.
  • Company has a healthy liquidity position with current ratio of 2.07822373617694.
  • The company has a high promoter holding of 74.98%.

 Limitations

  • The company has shown a poor profit growth of 4.14968990472484% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.2155532364316% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 2013 2579.3 2955.7 2159.3 2371.3
Total Expenditure 1628.3 1806.8 1814.7 1596.6 1689
Operating Profit 384.7 772.5 1141 562.7 682.3
Other Income 210.2 251.2 82.4 621.2 123.6
Interest 88.5 85 89.7 90.9 103.9
Depreciation 121.6 119.9 121.2 124.9 127.7
Exceptional Items 0 -203.8 0 0 0
Profit Before Tax 384.8 615 1012.5 968.1 574.3
Tax 128.9 124.3 231.6 163.1 123.9
Profit After Tax 255.9 490.7 780.9 805 450.4
Adjusted EPS (Rs) 2.53 4.85 7.72 7.95 4.45

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 6037.4 6347.4 7780 7836.9 8731.6
Total Expenditure 4412.7 4927.5 5472.6 6065.5 6553.2
Operating Profit 1624.7 1419.9 2307.4 1771.4 2178.4
Other Income 566.5 852.6 90.6 325.4 824.4
Interest 91.7 233.9 70.9 134.9 278.2
Depreciation 358.2 428.9 451.1 478.7 488.6
Exceptional Items 0 -52 -187.5 -319.3 -203.8
Profit Before Tax 1741.3 1557.7 1688.5 1163.9 2032.2
Tax 301.5 204.1 212.3 306 503
Net Profit 1485.7 1412.9 1476.2 857.9 1529.2
Adjusted EPS (Rs.) 14.06 13.22 14.42 8.38 15.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 102.4 102.4 102.4 102.4 101.2
Total Reserves 8466.8 11157.8 12642.1 13138.1 13538.2
Borrowings 2024.9 1511 609.5 126.4 3771
Other N/C liabilities 1361 1431.6 1569 1660.4 1624.3
Current liabilities 3119.2 3952.7 5163.5 4898.1 4051.2
Total Liabilities 15074.3 18155.5 20086.5 19925.4 23085.9
Assets
Net Block 3932.5 4109 4112 4335.9 4184.1
Capital WIP 674.9 552.6 570.5 384 739.3
Intangible WIP 0 0 0 0 0
Investments 4190.5 6404.1 6470.6 4897.5 4677.7
Loans & Advances 1558.9 1605 2398.1 2424.6 4626
Other N/C Assets 142.2 188.7 161.1 175.8 439.5
Current Assets 4575.3 5296.1 6374.2 7707.6 8419.3
Total Assets 15074.3 18155.5 20086.5 19925.4 23085.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1796.5 1625.9 1688.5 1163.9 2032.2
Adjustment -51.7 100.7 611.4 761.1 475.1
Changes in Assets & Liabilities -852 -344.8 191.1 -382.8 -1035.9
Tax Paid -312.2 -201.8 -263.8 -270 -393.2
Operating Cash Flow 580.7 1180.6 2227.2 1272.2 1078.2
Investing Cash Flow -712.6 54.6 -2713.8 586.2 -1959.7
Financing Cash Flow 64.9 -966.7 255.3 -1709.8 827
Net Cash Flow -67 268.5 -231.3 148.6 -54.5

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 74.98 74.98 74.98 74.98 74.98
zydus family trust (panka... - - 74.96 74.96 74.96
zydus family trust (mr. p... - 74.96 - - -
zydus family trust(mr. pa... 74.96 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 25.02 25.02 25.02 25.02 25.02
icici prudential focus eq... - - - - 1.27
investor education and pr... - - - - 0.15
kotak flexicap fund 2.44 2.35 2.40 2.42 2.39
llife insurance corporati... 6.23 6.23 5.98 5.30 4.57
llp 0.03 0.02 0.02 0.02 0.02
investor education and pr... 0.15 0.15 0.15 0.15 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Zydus Lifesciences gets final nod for Isosorbide Mononitrate Extended-Release Tablets16 Feb 2024, 4:09PM Zydus Lifesciences informs about investor conference14 Feb 2024, 10:48AM Zydus Lifesciences reports 27% rise in Q3 consolidated net profit9 Feb 2024, 5:07PM Zydus Lifesciences gets USFDA’s tentative approval for Dexamethasone Tablets9 Feb 2024, 3:39PM Zydus Lifesciences - Quaterly Results9 Feb 2024, 12:56PM Zydus Lifesciences - Quaterly Results9 Feb 2024, 12:56PM Zydus Lifesciences - Quaterly Results9 Feb 2024, 12:56PM Zydus Lifesciences gets final nods for Dexamethasone Tablets 8 Feb 2024, 4:13PM Zydus Lifesciences informs about investor conference7 Feb 2024, 10:38AM Zydus Lifesciences launches Relugolix30 Jan 2024, 10:41AM Zydus Lifesciences informs about press release30 Jan 2024, 10:21AM Zydus Lifesciences gets USFDA’s final approval for Gabapentin tablets25 Jan 2024, 3:27PM Zydus Lifesciences informs about details of loss of certificate23 Jan 2024, 5:13PM Zydus Lifesciences informs about press release19 Jan 2024, 9:43AM Zydus Lifesciences’ arm enters into licensing and supply agreement with Synthon BV19 Jan 2024, 9:05AM Zydus Lifesciences gets USFDA’s final approval for Pimavanserin Capsules, Pimavanserin Tablets18 Jan 2024, 9:10AM Zydus Lifesciences informs about certificate 8 Jan 2024, 10:46AM Zydus Lifesciences informs about disclosure3 Jan 2024, 12:16PM USFDA conducts inspection at Zydus Lifesciences’ API site in Ahmedabad23 Dec 2023, 4:04PM Zydus Lifesciences gets USFDA’s permission to initiate Phase II clinical study of ‘ZYIL1’ in patients with Parkinson’s disease18 Dec 2023, 9:59AM Zydus Lifesciences gets final nod to manufacture, market Lacosamide Tablets 16 Dec 2023, 3:01PM Zydus Lifesciences informs about press release 16 Dec 2023, 12:26PM Zydus Lifesciences informs about press release15 Dec 2023, 9:44AM Zydus Lifesciences gets USFDA’s final approval for Darunavir Tablets 600 mg, 800 mg15 Dec 2023, 9:22AM Zydus Lifesciences gets USFDA’s final approval for Cyclophosphamide Capsules14 Dec 2023, 3:49PM Zydus Lifesciences informs about loss of share certificate12 Dec 2023, 10:39AM Zydus Lifesciences informs about press release11 Dec 2023, 11:08AM Zydus Lifesciences’ arm, Daewoong Pharmaceutical enter into exclusive licensing agreement11 Dec 2023, 9:28AM Zydus Lifesciences gets USFDA’s final approval for Methylene Blue Injection6 Dec 2023, 2:59PM Zydus Lifesciences informs about press release6 Dec 2023, 10:18AM Zydus Lifesciences gets USFDA’s final approval for Ivabradine Tablets1 Dec 2023, 12:44PM Zydus Lifesciences submits newspaper publication11 Nov 2023, 12:10PM Zydus Lifesciences informs about press release10 Nov 2023, 4:32PM Zydus Lifesciences, Torrent sign licensing agreement to co-market Saroglitazar Mg10 Nov 2023, 4:00PM Zydus Lifesciences informs about investor presentation7 Nov 2023, 3:07PM Zydus Lifesciences informs about outcome of board meeting7 Nov 2023, 3:03PM Zydus Lifesciences reports 53% rise in Q2 consolidated net profit7 Nov 2023, 2:49PM Zydus Lifesciences informs about press release7 Nov 2023, 1:30PM Zydus Lifesciences - Quaterly Results7 Nov 2023, 12:01PM Zydus Lifesciences - Quaterly Results7 Nov 2023, 12:01PM Zydus Lifesciences - Quaterly Results7 Nov 2023, 12:01PM Zydus Lifesciences informs about press release6 Nov 2023, 10:17AM Zydus Lifesciences gets USFDA’s approval for ZITUVIMET6 Nov 2023, 9:10AM Zydus Lifesciences inks licensing agreement with Lupin 3 Nov 2023, 3:39PM Zydus Lifesciences signs co-marketing agreement with Guardant Health2 Nov 2023, 10:49AM Zydus Lifesciences’ arm acquires UK based LiqMeds Group31 Oct 2023, 3:52PM Zydus Lifesciences informs about press release30 Oct 2023, 11:01AM Zydus Lifesciences, Sun Pharma sign licensing agreement for co-marketing of Desidustat30 Oct 2023, 10:50AM Zydus Lifesciences informs about newspaper publication28 Oct 2023, 3:36PM Zydus Lifesciences to initiate Phase II clinical study of NLRP3 inhibitor ‘ZYIL1’25 Oct 2023, 12:07PM

Zydus Lifesciences Stock Price Analysis and Quick Research Report. Is Zydus Lifesciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Zydus Lifesciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Zydus Lifesciences cash from the operating activity was Rs 1078.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Zydus Lifesciences has a Debt to Equity ratio of 0.3536 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Zydus Lifesciences , the EPS growth was 80.3638143210112 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Zydus Lifesciences has OPM of 24.9484630537359 % which is a good sign for profitability.
     
  • ROE: Zydus Lifesciences have a average ROE of 11.3780185194141 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Zydus Lifesciences is Rs 895.75. One can use valuation calculators of ticker to know if Zydus Lifesciences share price is undervalued or overvalued.
Last Updated on:
Brief about Zydus Lifesciences

Zydus Lifesciences Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Zydus Lifesciences Ltd. is a leading pharmaceutical company in India that specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products. In this article, we will provide a comprehensive analysis of Zydus Lifesciences Ltd. stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Zydus Lifesciences Ltd. Share Price:

Zydus Lifesciences Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s share price and identify any trends or patterns. The company's share price has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Zydus Lifesciences Ltd. Balance Sheet:

Zydus Lifesciences Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets, while liabilities include loans, borrowings, and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s balance sheet and identify any red flags. The company's balance sheet has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Zydus Lifesciences Ltd. Annual Report:

Zydus Lifesciences Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Zydus Lifesciences Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Dividend:

Zydus Lifesciences Ltd. has a consistent dividend payout history. The company has paid dividends in every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Zydus Lifesciences Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Zydus Lifesciences Ltd. Quarterly Results:

Zydus Lifesciences Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Zydus Lifesciences Ltd. Stock Price:

The stock price of Zydus Lifesciences Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Zydus Lifesciences Ltd.'s stock price and identify potential buying opportunities. The stock price of Zydus Lifesciences Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Zydus Lifesciences Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Zydus Lifesciences Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Zydus Lifesciences Ltd. News:

Keeping up to date with the latest news about Zydus Lifesciences Ltd. is important for investors. Our website provides the latest news about Zydus Lifesciences Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Zydus Lifesciences Ltd. Concall:

Zydus Lifesciences Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Zydus Lifesciences Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Zydus Lifesciences Ltd. Transcripts:

Transcripts of Zydus Lifesciences Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Investor Presentations:

Zydus Lifesciences Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Zydus Lifesciences Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Zydus Lifesciences Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Zydus Lifesciences Ltd.'s promoters include the Zydus family. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Zydus Lifesciences Ltd. are relatively stable, which is a positive sign for long-term investors.

Zydus Lifesciences Ltd. Shareholders:

Zydus Lifesciences Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Zydus Lifesciences Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Zydus Lifesciences Ltd. is diverse, which is a positive sign for long-term investors.

Zydus Lifesciences Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Read More
X